CONGRESS PRESENTATIONS
IAS 2025
13th IAS Conference on HIV Science
Kigali, Rwanda
July 13-17, 2025
-
ViiV-Sponsored Data
-
Cabotegravir Prevention
Cooney EE, et al.
PrEP experiences and challenges among transgender women in the United States and Puerto Rico in the era of PrEP choice: findings from the ENCORE cohort
Dandachi D, et al.
One-year implementation outcomes of cabotegravir long-acting injectable PrEP in men who have sex with men (MSM) & transgender men (TGM): findings from the PILLAR study
Hawkins N, et al.
Indirect treatment comparison of the effectiveness of cabotegravir and lenacapavir for HIV pre-exposure prophylaxis (PrEP)
Islek D, et al.
HIV pre-exposure prophylaxis continuum and reasons for never using pre-exposure prophylaxis among transfeminine persons in the United States: results from the Transgender Women’s Internet Survey and Testing (TWIST)
Metzner AA, et al.
Real-world utilization and adherence of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States: results from the PrEPFACTS study using healthcare administrative claims data
Tims-Cook Z, et al.
Health care provider experiences after 12 months of implementing cabotegravir long-acting injectable PrEP (CAB LA) for Black women: results from the EBONI study
-
Cabotegravir Treatment
Altamirano J, et al.
Clinical outcomes among women in the OPERA cohort initiating CAB+RPV LA with viral loads ≥ 50 copies/mL
Blick G, et al.
Clinical outcomes at month 24 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND)
Felizarta F, et al.
Perspectives of people with HIV (PWH) 24 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)
Felizarta F, et al.
The power of choice: strong preference for CAB+RPV LA following rapid suppression with DTG/3TC in ART-naive people living with HIV
Hsu RK, et al.
Real-world effectiveness of CAB+RPV LA in individuals with HIV viremia at therapy initiation
Pozniak A, et al.
High virologic suppression and few virologic failures with long-acting cabotegravir + rilpivirine in treatment experienced virologically suppressed individuals from COMBINE-2 cohort in Europe
Wyen C, et al.
24-month outcomes of cabotegravir+rilpivirine long-acting every 2 months in a real‑world setting: effectiveness, adherence to injections, and participant-reported outcomes from people with HIV-1 in the German CARLOS cohort
-
Cabotegravir Treatment and Prevention
-
Dolutegravir-based Regimens
-
Other Disease-Related Content
Patel R, et al.
Data from the positive perspectives 3 study highlights the continued need for expansion of awareness, belief and confidence in undetectable equals untransmittable (U=U)
Patel R, et al.
Joint patient-provider decision making was associated with improvements in quality of life, adherence and treatment satisfaction for people living with HIV in the positive perspectives 3 study
Patel R, et al.
Treatment satisfaction was linked to improved adherence, and mental, physical, sexual and overall health among people living with HIV in the positive perspectives 3 study
-
-
ViiV-Supported & Collaborative Data
-
Cabotegravir Prevention
Aranha T, et al.
PrEP Choice in the real world: Understanding preferences among sexually and gender-diverse youth in Northeastern Brazil
Lebelo K, et al.
Choices in motion: how young people in the PrEPared to Choose study (Cape Town, South Africa) navigate PrEP product switching
Leite BO, et al.
Equivalent performance of HIV Oral Fluid Self-Testing and Rapid Testing compared to Nucleic Acid Amplification Test in Screening Adolescents for Long-Acting Injectable Cabotegravir in Brazil
Martin CE, et al.
Experiences with HIV testing among clients initiating CAB-LA: a case series from South Africa
Moore M, et al.
Model-based efficacy of long-acting cabotegravir by time since last injection among cisgender men and transgender women enrolled in HPTN 083
Pike C, et al.
Characteristics of early non-persistors on Cabotegravir long-acting (injectable PrEP) compared to persistent users in the PrEPared to Choose study in Cape Town, South Africa
Pike C, et al.
Investigating adolescent-friendly HIV prevention platforms as novel spaces for obesity interventions
Pike C, et al.
Tracking injectable PrEP use and persistence amongst South African adolescents and young people in an era of PrEP choice
Pimenta C, et al.
Understanding preferences and transitioning between oral and injectable PrEP: insights from ImPrEP CAB Brasil Study
Roos E, et al.
Prevalence and incidence of chlamydia and gonorrhoea infections in adolescent females using long acting injectable cabotegravir as HIV pre-exposure prophylaxis in South Africa, Zimbabwe and Uganda: results from HPTN 084-01
Rousseau E, et al.
Characterizing latent profiles of young long-acting injectable PrEP users in Cape Town, South Africa
Segawa I, et al.
High levels of autonomous decision-making among women receiving multi-method pre-exposure prophylaxis (PrEP) counseling through the CATALYST study in sub-Saharan Africa
Yoseph M, et al.
Evaluating CAB-LA Concentration and Breastmilk Transfer in Postpartum PrEP: Results from the Tshireletso PK Substudy
Zeballos D, et al.
Navigating Choices: Anticipated Drawbacks to PrEP Modalities Among Sexual and Gender Diverse Adolescents in Brazil
-
Cabotegravir Treatment
-
Dolutegravir-based Regimens
Brites C, et al.
The Impact of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Positive People with CD4 <200 Cells/mm³ Initiating Dolutegravir/Lamivudine Dual Therapy: DOLCE Study Findings
Cordova E, et al.
Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations: a subanalysis of the D2ARLING study
Farirai J, et al.
Virological outcomes of adolescents switched to dolutegravir based regimens at Botswana-Baylor Children’s Clinical Centre of Excellence (BBCCCOE), 2016 to 2023
Figueroa M, et al.
Impact of Dual Therapy on Weight Gain and Metabolic Outcomes in Naïve People living with HIV (PLHIV) with CD4 Counts <200 Cells/mm3: Findings from the DOLCE Study
Ombajo LA, et al.
Efficacy and safety of switching to dolutegravir/lamivudine dual therapy from bictegravir/emtricitabine/tenofovir alafenamide among virally suppressed older adults ≥60 years: week 24 results from the Sungura study
Ombajo LA, et al.
Is exclusion of tenofovir from antiretroviral regimens safe in Africa: insights on hepatitis B from the switch to DTG/3TC (Sungura) study
Rolle CP, et al.
Patient-Reported Outcomes among virally suppressed people living with HIV switching to dolutegravir/lamivudine vs. continuing bictegravir/emtricitabine/tenofovir alafenamide from the randomized DYAD study
Wyncoll J, et al.
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial
-
Other Disease-Related Content
-
